Ceribell, Inc. reported an insider transaction on March 3, 2026 in which its Senior Vice President of Finance and Public Affairs, David Foehr, sold 4,560 shares of common stock at $17.80 per share, generating proceeds of $81,168.
On the same day, Foehr also exercised options to acquire 4,560 shares of Ceribell common stock at an exercise price of $4.70 per share, representing a total exercise cost of $21,432. Both the sale and the option exercise were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that the company says was adopted on September 4, 2025.
The insider sale occurred amid recent share-price movement: Ceribell's stock has fallen 8.4% over the prior week, while remaining more than 50% higher than it was six months earlier. According to InvestingPro analysis cited by the company, CBLL is currently trading above its Fair Value and is classified among overvalued stocks in that dataset.
Separately, Ceribell announced several corporate developments. The company said it received FDA Breakthrough Device Designation for its Large Vessel Occlusion - LVO - stroke detection monitor. The device pairs existing EEG hardware with an AI-based algorithm and is intended to improve early detection of LVO strokes in hospital settings.
Ceribell also disclosed that Lucian Iancovici resigned from its board of directors effective December 31, 2025. The company stated that no disagreements related to operations or policies were cited in connection with the resignation.
On the research and market front, BTIG reiterated a Buy rating on Ceribell and maintained a $30.00 price target, calling for nearly 30% year-over-year revenue growth for 2026.
Finally, Ceribell extended its office leases in Sunnyvale, California, through January 2028. The leased space covers approximately 11,607 square feet and carries a monthly rent of $34,821.
Context and mechanics
The combined set of disclosures includes an executive share sale and option exercise under a pre-existing trading plan plus operational updates spanning regulatory progress, board composition, analyst coverage and real estate commitments. The company-provided valuation note from InvestingPro indicates a view that the stock is trading above its computed Fair Value.